Rep. Gilbert Ray Cisneros, Jr. Buys Shares of Alkermes plc (NASDAQ:ALKS)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Alkermes plc (NASDAQ:ALKS). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Alkermes stock on September 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.

Alkermes Stock Down 1.3%

ALKS stock opened at $39.73 on Wednesday. The company has a market capitalization of $6.67 billion, a price-to-earnings ratio of 104.56 and a beta of 0.32. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.85 and a current ratio of 2.30. The business’s 50 day moving average price is $45.55 and its two-hundred day moving average price is $43.50. Alkermes plc has a fifty-two week low of $27.00 and a fifty-two week high of $55.67.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Baker BROS. Advisors LP increased its position in shares of Alkermes by 23.7% during the fourth quarter. Baker BROS. Advisors LP now owns 10,012,267 shares of the company’s stock valued at $280,143,000 after acquiring an additional 1,920,916 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Alkermes by 2.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 4,522,378 shares of the company’s stock worth $159,850,000 after buying an additional 109,595 shares during the last quarter. Commodore Capital LP lifted its stake in Alkermes by 18.3% during the 1st quarter. Commodore Capital LP now owns 4,200,000 shares of the company’s stock valued at $148,512,000 after acquiring an additional 650,000 shares during the period. First Trust Advisors LP raised its holdings in shares of Alkermes by 104.2% during the first quarter. First Trust Advisors LP now owns 2,968,785 shares of the company’s stock valued at $104,976,000 after purchasing an additional 1,514,783 shares during the last quarter. Finally, Affinity Asset Advisors LLC boosted its holdings in Alkermes by 35.0% in the first quarter. Affinity Asset Advisors LLC now owns 1,350,000 shares of the company’s stock worth $47,736,000 after purchasing an additional 350,000 shares during the last quarter. Institutional investors own 95.21% of the company’s stock.

Insider Activity at Alkermes

In other Alkermes news, SVP Christian Nichols sold 7,576 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $49.23, for a total value of $372,966.48. Following the transaction, the senior vice president owned 102,193 shares of the company’s stock, valued at approximately $5,030,961.39. This represents a 6.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Craig Hopkinson sold 9,000 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $46.99, for a total value of $422,910.00. Following the completion of the transaction, the executive vice president directly owned 65,389 shares in the company, valued at $3,072,629.11. The trade was a 12.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 76,150 shares of company stock valued at $3,752,181 in the last quarter. 4.59% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

ALKS has been the subject of several recent research reports. The Goldman Sachs Group reissued a “neutral” rating and set a $50.00 price objective on shares of Alkermes in a research report on Thursday, September 24th. TD Cowen reaffirmed a “buy” rating on shares of Alkermes in a research report on Monday, September 21st. Piper Sandler reaffirmed an “overweight” rating and issued a $65.00 target price (up from $43.00) on shares of Alkermes in a research report on Tuesday, July 28th. JPMorgan Chase & Co. increased their price target on shares of Alkermes from $60.00 to $61.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 29th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $63.00 price target (up from $45.00) on shares of Alkermes in a research note on Monday, July 20th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $54.47.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases. The company’s portfolio addresses conditions including addiction, schizophrenia, bipolar disorder and amyotrophic lateral sclerosis (ALS), with an emphasis on long-acting injectable, extended-release and other drug-delivery technologies.

Its marketed products include Vivitrol, an extended-release injectable formulation of naltrexone used to treat alcohol dependence and prevent opioid dependence relapse; Aristada, a long-acting injectable formulation of aripiprazole lauroxil for the treatment of schizophrenia in adults; Lybalvi, an oral combination of olanzapine and samidorphan for schizophrenia and bipolar I disorder; and Exservan, an oral film formulation of riluzole for ALS.

Founded in 1987, Alkermes is headquartered in Dublin, Ireland, with operations and corporate offices in the United States, including Waltham, Massachusetts.